drugset / Trial / NCT03653338

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

NCT03653338 ↗

Phase 1/2 Recruiting 5 enrolled Paul Szabolcs
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate what effect, if any, mismatched unrelated volunteer donor and/or haploidentical related donor stem cell transplant may have on severe sickle cell disease and other transfusion dependent anemias. By using mismatched unrelated volunteer donor and/or haploidentical related donor stem cells, this study will increase the number of patients who can undergo a stem cell transplant for their specified disease. Additionally, using a T-cell depleted approach should reduce the incidence of graft-versus-host disease which would otherwise be increased in a mismatched transplant setting.

Timeline

Start
2018-08-02
Primary completion
2026-08-01
Completion
2027-08-01

Drugs

EvaluationDrugModalityDoseRoute
Background Alemtuzumab Monoclonal antibody — —
Background Fludarabine Small molecule — —
Background Hydroxyurea Other / unclassified — —
Background Rituximab Monoclonal antibody — —
Background Thiotepa Other / unclassified — —